Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) (APEX)
(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients
Sponsor: Portola Pharmaceuticals
A PHASE3 clinical study on Venous Thromboembolism (VTE), this trial is completed. The trial is conducted by Portola Pharmaceuticals and has accumulated 11 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2023 — Dec 2023 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Jan 2021 — Sep 2023 [monthly]
Completed PHASE3
-
Oct 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Oct 2018 [monthly]
Completed PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Oct 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Mar 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Portola Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarhus N, Denmark , Afula, Israel , Altenburg, Germany , Alytus, Lithuania , Angers, France , Annapolis, United States , Arequipa, Peru , Arkhangelsk, Russia , Arras, France , Ashkelon, Israel and 358 more locations